ArticleScientific reports2026
Lipid accumulation product (LAP): a key indicator for metabolic dysregulation and inflammatory status in obesity.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Lipid Accumulation Product (LAP) is recognized as an indicator of lipid-induced cellular stress. While its predictive value for conditions like diabetes, liver disease, and metabolic syndrome is established, its specific correlations with individual metabolic and hematological markers within the context of obesity remain less defined. This study sought to comprehensively investigate the links between LAP and a spectrum of metabolic and hematological biomarkers in individuals with obesity. This cross-sectional study involved 304 obese participants. Standard anthropometric measurements [weight, height, waist and hip circumference (WC, HC)] were taken, and dietary intake was assessed via a food frequency questionnaire. Blood samples were analyzed for glucose, insulin, hemoglobin A1C, serum lipids [total cholesterol, triglycerides, low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C)], and a complete blood cell count. LAP was calculated using WC and triglyceride levels. Participants were categorized into three tertiles based on their LAP values. Individuals in the highest LAP tertile had significantly higher body weight, body mass index, WC, and waist-to-hip ratio than those in the lowest tertile (all P < 0.05). Higher LAP tertiles were also associated with increased systolic and diastolic blood pressure, total cholesterol, triglycerides, and reduced HDL-C levels after adjustment for potential confounders. In addition, white blood cell count and mean corpuscular hemoglobin remained significantly higher across LAP tertiles in the fully adjusted models. Supplementary receiver operating characteristic (ROC) analysis demonstrated good discriminatory performance of LAP for identifying metabolic syndrome (AUC = 0.833; 95% CI: 0.779-0.887). Higher LAP was independently associated with an adverse cardiometabolic profile, characterized by greater adiposity, unfavorable lipid parameters, elevated blood pressure, and selected hematological alterations in adults with obesity. These findings support the potential utility of LAP as a simple and accessible marker for identifying individuals at increased cardiometabolic risk. However, prospective studies are needed to determine its predictive value and establish temporal relationships.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.